Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Multiple Myeloma (RRMM)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03989414
What this trial is testing

Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Celgene 424
Testing effectiveness (Phase 2)WithdrawnNCT03856112
What this trial is testing

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myelomat(11;14) Negative
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT04824794
What this trial is testing

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)Diffuse Large B Cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)
Genmab 130
Large-scale testing (Phase 3)Active Not RecruitingNCT06158841
What this trial is testing

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 421
Testing effectiveness (Phase 2)Active Not RecruitingNCT04790474
What this trial is testing

Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

Who this might be right for
Multiple Myeloma in RelapseRefractory Multiple Myeloma
Tel-Aviv Sourasky Medical Center 61
Testing effectiveness (Phase 2)Ended earlyNCT04776018
What this trial is testing

TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Takeda 27
Large-scale testing (Phase 3)Active Not RecruitingNCT04975997
What this trial is testing

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene 939
Testing effectiveness (Phase 2)Study completedNCT06212596
What this trial is testing

Selinexor, Cyclophosphamide and Prednisone in Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
University of Leeds 66
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07695740
What this trial is testing

Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Excyte Biopharma Ltd 64
Early research (Phase 1)Looking for participantsNCT05759793
What this trial is testing

CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia
Nanjing IASO Biotechnology Co., Ltd. 12
Early research (Phase 1)WithdrawnNCT04998747
What this trial is testing

Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Amgen
Testing effectiveness (Phase 2)Temporarily pausedNCT06876142
What this trial is testing

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI) 54
Large-scale testing (Phase 3)Looking for participantsNCT07222761
What this trial is testing

Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 915
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06333509
What this trial is testing

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Who this might be right for
Multiple MyelomaPrimary Plasma Cell Leukemia
CARsgen Therapeutics Co., Ltd. 166
Early research (Phase 1)Study completedNCT03650491
What this trial is testing

FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma With Failed Remission
Fortis Therapeutics, Inc. 31
Early research (Phase 1)Looking for participantsNCT07003555
What this trial is testing

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital 18
Testing effectiveness (Phase 2)Study completedNCT04191616
What this trial is testing

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Amgen 54
Testing effectiveness (Phase 2)Study completedNCT03544281
What this trial is testing

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 153
Early research (Phase 1)WithdrawnNCT05918250
What this trial is testing

MRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
Large-scale testing (Phase 3)Looking for participantsNCT05519085
What this trial is testing

Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Celgene 810
Next Page